At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 41 enrolled
Drug / intervention
VeraCept +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Single-Blind, Comparative Bioavailability Study to Assess the Pharmacokinetic Properties of VeraCept® Intrauterine Contraceptive vs ParaGard® in Healthy, Post-Menarcheal Women
In Brief
A Phase 3 clinical trial evaluating VeraCept and ParaGard for Women at Risk for Pregnancy. Completed, enrolled 41 participants across 2 sites.
Detailed Summary
to Assess the Pharmacokinetic Properties of VeraCept® Intrauterine Contraceptive vs ParaGard® in Healthy, Post- Menarcheal Women
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWomen at Risk for Pregnancy
CountriesUnited States
CollaboratorsSynteract, Inc.
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartDec 2018
First PostedDec 2018
Primary CompletionDec 2019
Study CompletionAug 2024
TodayJul 2026
First PostedDec 24, 2018
Enrollment StartDec 17, 2018
Primary CompletionDec 30, 2019
Study CompletionAug 1, 2024
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 7.5 years ago
Interventions
VeraCeptdrug
VeraCept Intrauterine Device (IUD)
ParaGarddrug
ParaGard intrauterine copper contraceptive